These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 24472251)

  • 21. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
    Ota T; Yamamuro K; Okazaki K; Kishimoto T
    Drug Des Devel Ther; 2021; 15():1965-1969. PubMed ID: 34007156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
    Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
    BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study.
    Naya N; Sakai C; Okutsu D; Kiguchi R; Fujiwara M; Tsuji T; Iwanami A
    Neuropsychopharmacol Rep; 2021 Mar; 41(1):26-39. PubMed ID: 33305542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients.
    Cunill R; Castells X; Tobias A; Capellà D
    Psychopharmacology (Berl); 2016 Jan; 233(2):187-97. PubMed ID: 26446868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder.
    Newcorn JH; Huss M; Connor DF; Hervás A; Werner-Kiechle T; Robertson B
    J Dev Behav Pediatr; 2020 Sep; 41(7):565-570. PubMed ID: 32482970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Deavenport-Saman A; Friedman S; LaRosa A; Loe IM; Mittal S; Tulio S; Vanderbilt D; Blum NJ
    JAMA; 2021 May; 325(20):2067-2075. PubMed ID: 33946100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis.
    Ruggiero S; Clavenna A; Reale L; Capuano A; Rossi F; Bonati M
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1578-90. PubMed ID: 25156577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
    PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
    Michelini G; Lenartowicz A; Vera JD; Bilder RM; McGough JJ; McCracken JT; Loo SK
    J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):415-426. PubMed ID: 35963559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R; Castells X; Tobias A; Capellà D
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.
    Sayer GR; McGough JJ; Levitt J; Cowen J; Sturm A; Castelo E; McCracken JT
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):882-888. PubMed ID: 27483130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review.
    Neuchat EE; Bocklud BE; Kingsley K; Barham WT; Luther PM; Ahmadzadeh S; Shekoohi S; Cornett EM; Kaye AD
    Neurol Int; 2023 May; 15(2):697-707. PubMed ID: 37218982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of physical exercise in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis of randomized control trials.
    Cerrillo-Urbina AJ; García-Hermoso A; Sánchez-López M; Pardo-Guijarro MJ; Santos Gómez JL; Martínez-Vizcaíno V
    Child Care Health Dev; 2015 Nov; 41(6):779-88. PubMed ID: 25988743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
    Schneider G; Banaschewski T; Feldman BL; Gustafsson PA; Murphy B; Reynolds M; Coghill DR; Spalding WM
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.